Full Text Journal Articles by
Author Teresa Lozano

Advertisement

Find full text journal articles






Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.

Laura Arribillaga, Iciar Echeverria, Viriginia Belsue, Timothy Gomez, Teresa Lozano, Noelia Casares, Lorea Villanueva, Sonia Domingos-Pereira, Pedro J Romero, Denise Nardelli-Haefliger, Sandra Hervás-Stubbs, Pablo Sarobe, María Josefa Rodriguez, José L Carrascosa, Thomas Zürcher, Juan José Lasarte,

BACKGROUND:In vivo targeting of human papillomavirus (HPV) derived antigens to dendritic cells might constitute an efficient immunotherapeutic strategy against cervical cancer. In previous works, we have shown that the extra domain A from murine fibronectin (mEDA) can be used to target antigens to toll-like receptor 4 (TLR4) expressing dendritic cells ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2020, 8(1):]

Cited: 0 times

View full text PDF listing >>



A distal enhancer at risk locus 11q13.5 promotes suppression of colitis by Treg cells.

Rabab Nasrallah, Charlotte J Imianowski, Lara Bossini-Castillo, Francis M Grant, Mikail Dogan, Lindsey Placek, Lina Kozhaya, Paula Kuo, Firas Sadiyah, Sarah K Whiteside, Maxwell R Mumbach, Dafni Glinos, Panagiota Vardaka, Carly E Whyte, Teresa Lozano, Toshitsugu Fujita, Hodaka Fujii, Adrian Liston, Simon Andrews, Adeline Cozzani, Jie Yang, Suman Mitra, Enrico Lugli, Howard Y Chang, Derya Unutmaz, Gosia Trynka, Rahul Roychoudhuri,

Genetic variations underlying susceptibility to complex autoimmune and allergic diseases are concentrated within noncoding regulatory elements termed enhancers1. The functions of a large majority of disease-associated enhancers are unknown, in part owing to their distance from the genes they regulate, a lack of understanding of the cell types in which ... Read more >>

Nature (Nature)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Association between an elevated inter-arm systolic blood pressure difference, the ankle-brachial index, and mortality in patients with diabetes mellitus.

Javier Ena, Santiago Pérez-Martín, Carlos R Argente, Teresa Lozano,

OBJECTIVES:To estimate the prevalence of an inter-arm blood pressure difference greater than 10mmHg in patients with type 2 diabetes, and the association of this measurement with the presence of a low ankle-brachial index and mortality at 5-year follow-up. METHOD:A validated blood pressure measurement protocol was used. The blood pressure was ... Read more >>

Clin Investig Arterioscler (Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis)
[2020, 32(3):94-100]

Cited: 0 times

View full text PDF listing >>



One-year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry.

Juan Miguel Ruiz-Nodar, María Asunción Esteve-Pastor, Jose Miguel Rivera-Caravaca, Miriam Sandín, Teresa Lozano, Nuria Vicente-Ibarra, Esteban Orenes-Piñero, Manuel Jesús Macías, Vicente Pernías, Luna Carrillo, Elena Candela, Andrea Veliz, Antonio Tello-Montoliu, Juan Gabriel Martínez Martínez, Francisco Marín,

BACKGROUND:Prasugrel and ticagrelor have demonstrated higher efficacy than clopidogrel in their main clinical trials for patients with acute coronary syndrome (ACS). However, the long-term prognosis and different clinical characteristics related to the type of antiplatelet prescription in current clinical practice ACS patients have not been analysed in depth. The objective ... Read more >>

Br J Clin Pharmacol (British journal of clinical pharmacology)
[2020, 86(6):1052-1061]

Cited: 0 times

View full text PDF listing >>



Genetic Modification of CD8+ T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies.

Teresa Lozano, Silvia Chocarro, Celia Martin, Aritz Lasarte-Cia, Cynthia Del Valle, Marta Gorraiz, Patricia Sarrión, Marina Ruiz de Galarreta, Amaia Lujambio, Sandra Hervás-Stubbs, Pablo Sarobe, Noelia Casares, Juan J Lasarte,

Adoptive immunotherapy with ex vivo-expanded tumor-infiltrating lymphocytes (TILs) has achieved objective clinical responses in a significant number of patients with cancer. The failure of many patients to develop long-term tumor control may be, in part, due to exhaustion of transferred T cells in the presence of a hostile tumor microenvironment. ... Read more >>

Front Immunol (Frontiers in immunology)
[2019, 10:2990]

Cited: 0 times

View full text PDF listing >>



FOXP3 Inhibitory Peptide P60 Increases Efficacy of Cytokine-induced Killer Cells Against Renal and Pancreatic Cancer Cells.

Maria Fitria Setiawan, Oliver Rudan, Annabelle Vogt, Maria A Gonzalez-Carmona, Bettina Langhans, Roland Schmidt-Wolf, Francesca Garofano, Christian P Strassburg, Juan J Lasarte, Noelia Casares, Teresa Lozano, Hans Weiher, Ingo G H Schmidt-Wolf,

BACKGROUND/AIM:Cytokine-induced killer (CIK) cells are ex vivo expanded major histocompatibility complex (MHC)-unrestricted cytotoxic cells with promising effects against a variety of cancer types. Regulatory T-cells (T-reg) have been shown to reduce the effectiveness of CIK cells against tumor cells. Peptide P60 has been shown to inhibit the immunosuppressive functions of ... Read more >>

Anticancer Res. (Anticancer research)
[2019, 39(10):5369-5374]

Cited: 0 times

View full text PDF listing >>



ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity.

Mario Martínez Soldevilla, Helena Villanueva, Daniel Meraviglia-Crivelli, Ashwathi Puravankara Menon, Marta Ruiz, Javier Cebollero, María Villalba, Beatriz Moreno, Teresa Lozano, Diana Llopiz, Álvaro Pejenaute, Pablo Sarobe, Fernando Pastor,

Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) blockade therapy is able to induce long-lasting antitumor responses in a fraction of cancer patients. Nonetheless, there is still room for improvement in the quest for new therapeutic combinations. ICOS costimulation has been underscored as a possible target to include with CTLA-4 blocking treatment. ... Read more >>

Mol. Ther. (Molecular therapy : the journal of the American Society of Gene Therapy)
[2019, 27(11):1878-1891]

Cited: 0 times

View full text PDF listing >>



Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations.

Teresa López-Fernández, Ana Martín-García, Inmaculada Roldán Rabadán, Cristina Mitroi, Pilar Mazón Ramos, Pablo Díez-Villanueva, Carlos Escobar Cervantes, Concepción Alonso Martín, Gonzalo Luis Alonso Salinas, Meritxell Arenas, Vicente Ignacio Arrarte Esteban, Francisco Ayala de La Peña, Antonio Castro Fernández, Héctor García Pardo, Ramón García-Sanz, José Ramón González Porras, Esteban López de Sá, Teresa Lozano, Pascual Marco Vera, Virginia Martínez Marín, Dolores Mesa Rubio, Ángel Montero, Gerard Oristrell, Armando Pérez de Prado, Sonia Velasco Del Castillo, Juan Antonio Virizuela Echaburu, Eduardo Zatarain-Nicolás, Manuel Anguita Sánchez, Juan Tamargo Menéndez, ,

Improvements in survival among cancer patients have revealed the clinical impact of cardiotoxicity on both cardiovascular and hematological and oncological outcomes, especially when it leads to the interruption of highly effective antitumor therapies. Atrial fibrillation is a common complication in patients with active cancer and its treatment poses a major ... Read more >>

Rev Esp Cardiol (Engl Ed) (Revista Espanola De Cardiologia (English Ed.))
[2019, 72(9):749-759]

Cited: 0 times

View full text PDF listing >>



Under-prescription of novel antiplatelet drugs in patients with acute coronary syndrome and previous cardiovascular disease.

Esteban Orenes-Piñero, María A Esteve-Pastor, Juan M Ruiz-Nodar, Miriam Quintana-Giner, Andrea Veliz-Martínez, Antonio Tello-Montoliú, Manuel J Macías-Villanego, Vicente Pernías-Escrig, Nuria Vicente-Ibarra, Luna Carrillo-Alemán, Miriam Sandín-Rollán, Juan Martínez, Teresa Lozano, José M Rivera-Caravaca, Francisco Marín,

BACKGROUND:Patients with acute coronary syndrome (ACS) and previous cardiovascular disease (CVD) (stroke, peripheral arterial disease [PAD] or coronary artery disease [CAD]) are at high risk of serious events and mortality. Current clinical guidelines recommend new antiplatelet drugs (NADs) for high cardiovascular risk patients with ACS; however, these drugs are underused ... Read more >>

Minerva Med. (Minerva medica)
[2019, 110(5):410-418]

Cited: 0 times

View full text PDF listing >>



Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma.

Isabel Vivas, Kristina Iribarren, Teresa Lozano, David Cano, Aritz Lasarte-Cia, Silvia Chocarro, Marta Gorraiz, Pablo Sarobe, Sandra Hervás-Stubbs, José Ignacio Bilbao, Noelia Casares, Juan José Lasarte,

PURPOSE:To evaluate the therapeutic efficacy of irreversible electroporation (IRE) combined with the intratumoral injection of the immunogenic adjuvant poly-ICLC (polyinosinic-polycytidylic acid and poly-L-lysine, a dsRNA analog mimicking viral RNA) inmediately before IRE. MATERIALS AND METHODS:Mice and rabbits bearing hepatocellular carcinoma tumors (Hepa.129 and VX2 tumor models, respectively) were treated with ... Read more >>

J Vasc Interv Radiol (Journal of vascular and interventional radiology : JVIR)
[2019, 30(7):1098-1105]

Cited: 0 times

View full text PDF listing >>



Bacterial DNA translocation contributes to systemic inflammation and to minor changes in the clinical outcome of liver transplantation.

Gonzalo P Rodríguez-Laiz, Pedro Zapater, Paola Melgar, Cándido Alcázar, Mariano Franco, Paula Giménez, Sonia Pascual, Pablo Bellot, José M Palazón, María Rodríguez, Fernando Carnicer, Patricio Más-Serrano, José M González-Navajas, Luís Gómez, José Such, Félix Lluís, Rubén Francés, ,

Bacterial (bact)DNA is an immunogenic product that frequently translocates into the blood in cirrhosis. We evaluated bactDNA clearance in patients undergoing liver transplantation (LT) and its association with inflammation and clinically relevant complications. We prospectively included patients consecutively admitted for LT in a one-year follow-up study. We evaluated bactDNA before ... Read more >>

Sci Rep (Scientific reports)
[2019, 9(1):835]

Cited: 0 times

View full text PDF listing >>



Switching of Oral P2Y12 Inhibitor Treatment in Patients with Acute Coronary Syndrome: Prevalence, Predictors, and Prognosis.

Luna Carrillo-Aleman, Francisco Marín, José M Rivera-Caravaca, Nuria Vicente-Ibarra, Elena Candela-Sanchez, Maria A Esteve-Pastor, Teresa Lozano, Miriam Sandín-Rollan, Vicente Pernias-Escrig, Manuel Macías, Miriam Quintana-Giner, Andrea Veliz, Esteban Orenes-Piñero, Juan G Martínez-Martínez, Juan M Ruiz-Nodar,

BACKGROUND AND OBJECTIVE:Dual antiplatelet therapy is one of the main treatments in acute coronary syndrome (ACS). Switching antiplatelet agents may be necessary in some patients to improve efficacy or safety. The objective of this study was to determine the prevalence, predictors, and implications of clinical switching in patients during hospital ... Read more >>

Clin Drug Investig (Clinical drug investigation)
[2019, 39(3):275-283]

Cited: 0 times

View full text PDF listing >>



Conservatively managed patients with non-ST-segment elevation acute coronary syndrome are undertreated with indicated medicines.

Elena Candela, Francisco Marín, José Miguel Rivera-Caravaca, Nuria Vicente Ibarra, Luna Carrillo, María Asunción Esteve-Pastor, Teresa Lozano, Manuel Jesús Macías, Vicente Pernias, Miriam Sandín, Esteban Orenes-Piñero, Miriam Quintana-Giner, Ignacio Hortelano, Beatriz Villamía, Andrea Veliz, Mariano Valdés, Juan G Martínez-Martínez, Juan M Ruiz-Nodar,

INTRODUCTION AND AIMS:Patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) are often managed conservatively. Clinical practice guidelines recommend treating these patients with the same pharmacological drugs as those who receive invasive treatment. We analyze the use of new antiplatelet drugs (NADs) and other recommended treatments in people discharged following an NSTE-ACS ... Read more >>

PLoS ONE (PloS one)
[2018, 13(11):e0208069]

Cited: 0 times

View full text PDF listing >>



Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome.

Nuria Vicente-Ibarra, Francisco Marín, Vicente Pernías-Escrig, Miriam Sandín-Rollán, Laura Núñez-Martínez, Teresa Lozano, Manuel Jesús Macías-Villaniego, Luna Carrillo-Alemán, Elena Candela-Sánchez, Elena Guzmán, María Asunción Esteve-Pastor, Esteban Orenes-Piñero, Mariano Valdés, José Miguel Rivera-Caravaca, Juan M Ruiz-Nodar,

BACKGROUND:Anemia is frequent in acute coronary syndrome (ACS) patients and is associated with worse clinical outcomes. We aimed to investigate the therapeutic strategies, the use of novel P2Y12 inhibitors, and the prognostic implication of anemia in a "real world" cohort of ACS patients. METHODS:This is an observational and prospective registry ... Read more >>

Eur. J. Intern. Med. (European journal of internal medicine)
[2019, 61:48-53]

Cited: 0 times

View full text PDF listing >>



Chronic Kidney Disease and Third-Generation P2Y12 Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year.

Antonio Tello-Montoliu, Juan Miguel Ruiz-Nodar, María Asunción Esteve-Pastor, Andrea Véliz-Martínez, Esteban Orenes-Piñero, Manuel J Macías-Villanego, Teresa Lozano, Luna Carrillo-Alemán, Nuria Vicente-Ibarra, Vicente Pernias-Escrig, Juan G Martínez-Martínez, José Miguel Rivera-Caravaca, Francisco Marín,

Chronic kidney disease (CKD) is associated with worse clinical outcomes in patients with acute coronary syndrome. However, they are underrepresented in clinical trials. We aimed to investigate differences in prognosis of acute coronary syndrome patients with and without CKD, focusing on the use of novel P2Y12 receptor inhibitors. This multicenter ... Read more >>

J Clin Pharmacol (Journal of clinical pharmacology)
[2019, 59(2):295-302]

Cited: 0 times

View full text PDF listing >>



Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms.

Jon Celay, Teresa Lozano, Axel R Concepcion, Elena Beltrán, Francesc Rudilla, María José García-Barchino, Eloy F Robles, Obdulia Rabal, Irene de Miguel, Carlos Panizo, Noelia Casares, Julen Oyarzabal, Jesús Prieto, Juan F Medina, Juan José Lasarte, José Ángel Martínez-Climent,

Regulatory T (Treg) cells can weaken antitumor immune responses, and inhibition of their function appears to be a promising therapeutic approach in cancer patients. Mice with targeted deletion of the gene encoding the Cl-/HCO3- anion exchanger AE2 (also termed SLC4A2), a membrane-bound carrier involved in intracellular pH regulation, showed a ... Read more >>

Haematologica (Haematologica)
[2018, 103(6):1065-1072]

Cited: 1 time

View full text PDF listing >>



The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer.

Lorea Villanueva, Leyre Silva, Diana Llopiz, Marta Ruiz, Tamara Iglesias, Teresa Lozano, Noelia Casares, Sandra Hervas-Stubbs, María José Rodríguez, José L Carrascosa, Juan José Lasarte, Pablo Sarobe,

Tumor infiltrating lymphocytes have been associated with a better prognostic and with higher response rates in patients treated with checkpoint inhibiting antibodies, suggesting that strategies promoting tumor inflammation may enhance the efficacy of these currently available therapies. Our aim was thus to develop a new vaccination platform based on cold-inducible ... Read more >>

Oncoimmunology (Oncoimmunology)
[2018, 7(4):e1409321]

Cited: 1 time

View full text PDF listing >>



Therapeutic management and one-year outcomes in elderly patients with acute coronary syndrome.

Esteban Orenes-Piñero, Juan M Ruiz-Nodar, María Asunción Esteve-Pastor, Miriam Quintana-Giner, José Miguel Rivera-Caravaca, Andrea Veliz, Mariano Valdés, Manuel Macías, Vicente Pernias-Escrig, Nuria Vicente-Ibarra, Luna Carrillo, Miriam Sandín-Rollán, Elena Candela, Teresa Lozano, Francisco Marín,

Elderly represents a subgroup of high-risk ACS patients due to their advanced age and other comorbidities. Unfortunately, they are also often under-represented in many studies and clinical trials. Furthermore, cardiologists commonly find difficulties in the choice of the antiplatelet treatment and even on whether invasive revascularization should be used. In ... Read more >>

Oncotarget (Oncotarget)
[2017, 8(46):80182-80191]

Cited: 1 time

View full text PDF listing >>



Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes.

María Asunción Esteve-Pastor, Juan Miguel Ruíz-Nodar, Esteban Orenes-Piñero, José Miguel Rivera-Caravaca, Miriam Quintana-Giner, Andrea Véliz-Martínez, Antonio Tello-Montoliu, Vicente PerniasEscrig, Miriam Sandín Rollán, Nuria Vicente-Ibarra, Manuel Jesús MacíasVillanego, Elena Candela Sánchez, Luna Carrillo Alemán, Teresa Lozano, Mariano Valdés, Francisco Marín,

Current clinical guidelines of acute coronary syndromes (ACS) recommend the use of potent antiplatelet therapy, prasugrel or ticagrelor, because both drugs consistently reduce cardiovascular events.The aim of this study was to examine temporal changes in the use of optimal antiplatelet therapy in patients with ACS.A total of 1717 consecutive patients ... Read more >>

J. Cardiovasc. Pharmacol. Ther. (Journal of cardiovascular pharmacology and therapeutics)
[2018, 23(1):57-65]

Cited: 4 times

View full text PDF listing >>



Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA).

Mario Martínez Soldevilla, Sandra Hervas, Helena Villanueva, Teresa Lozano, Obdulia Rabal, Julen Oyarzabal, Juan José Lasarte, Maurizio Bendandi, Susana Inoges, Ascensión López-Díaz de Cerio, Fernando Pastor,

LAG3 receptor belongs to a family of immune-checkpoints expressed in T lymphocytes and other cells of the immune system. It plays an important role as a rheostat of the immune response. Focus on this receptor as a potential therapeutic target in cancer immunotherapy has been underscored after the success of ... Read more >>

PLoS ONE (PloS one)
[2017, 12(9):e0185169]

Cited: 6 times

View full text PDF listing >>



Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor.

Teresa Lozano, Marta Gorraiz, Aritz Lasarte-Cía, Marta Ruiz, Obdulia Rabal, Julen Oyarzabal, Sandra Hervás-Stubbs, Diana Llopiz, Pablo Sarobe, Jesús Prieto, Noelia Casares, Juan José Lasarte,

Although T regulatory cells (Treg) are essential for the prevention of autoimmune diseases, their immunoregulatory function restrains the induction of immune responses against cancer. Thus, development of inhibitors of FOXP3, a key transcription factor for the immunosuppressive activity of Treg, might give new therapeutic opportunities. In a previous work we ... Read more >>

Oncotarget (Oncotarget)
[2017, 8(42):71709-71724]

Cited: 4 times

View full text PDF listing >>



A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.

Daniel Ajona, Sergio Ortiz-Espinosa, Haritz Moreno, Teresa Lozano, María J Pajares, Jackeline Agorreta, Cristina Bértolo, Juan J Lasarte, Silvestre Vicent, Kai Hoehlig, Axel Vater, Fernando Lecanda, Luis M Montuenga, Ruben Pio,

Disruption of the programmed cell death protein 1 (PD-1) pathway with immune checkpoint inhibitors represents a major breakthrough in the treatment of non-small cell lung cancer. We hypothesized that combined inhibition of C5a/C5aR1 and PD-1 signaling may have a synergistic antitumor effect. The RMP1-14 antibody was used to block PD-1, ... Read more >>

Cancer Discov (Cancer discovery)
[2017, 7(7):694-703]

Cited: 32 times

View full text PDF listing >>



Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance.

Marta Consuegra-Fernández, Mario Martínez-Florensa, Fernando Aranda, José de Salort, Noelia Armiger-Borràs, Teresa Lozano, Noelia Casares, Juan José Lasarte, Pablo Engel, Francisco Lozano,

The CD6 lymphocyte receptor has been involved in the pathophysiology of different autoimmune disorders and is now considered a feasible target for their treatment. In vitro data show the relevance of CD6 in the stabilization of adhesive contacts between T-cell and antigen-presenting cells, and the modulation of T-cell receptor signals. ... Read more >>

Front Immunol (Frontiers in immunology)
[2017, 8:594]

Cited: 4 times

View full text PDF listing >>



Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.

Sarita M Fernandez-Poma, Diego Salas-Benito, Teresa Lozano, Noelia Casares, Jose-Ignacio Riezu-Boj, Uxua Mancheño, Edurne Elizalde, Diego Alignani, Natalia Zubeldia, Itziar Otano, Enrique Conde, Pablo Sarobe, Juan Jose Lasarte, Sandra Hervas-Stubbs,

Recent studies have found that tumor-infiltrating lymphocytes (TIL) expressing PD-1 can recognize autologous tumor cells, suggesting that cells derived from PD-1+ TILs can be used in adoptive T-cell therapy (ACT). However, no study thus far has evaluated the antitumor activity of PD-1-selected TILs in vivo In two mouse models of ... Read more >>

Cancer Res. (Cancer research)
[2017, 77(13):3672-3684]

Cited: 12 times

View full text PDF listing >>



Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry.

José Miguel Rivera-Caravaca, Juan M Ruiz-Nodar, Antonio Tello-Montoliu, María Asunción Esteve-Pastor, Andrea Veliz-Martínez, Esteban Orenes-Piñero, Mariano Valdés, Vicente Pernias-Escrig, Miriam Sandin-Rollán, Nuria Vicente-Ibarra, Manuel J Macías-Villanego, Elena Candela-Sánchez, Teresa Lozano, Luna Carrillo-Alemán, Francisco Marín,

BACKGROUND:Being overweight increases the risk of cardiovascular diseases and mortality. However, among high-body-weight patients with established acute coronary syndrome (ACS) this evidence is not clear. In this scenario, a low body weight (LBW) has been proposed to confer higher prognostic risk and higher bleeding risk with new P2Y12 inhibitors. AIMS:We ... Read more >>

Eur J Cardiovasc Nurs (European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology)
[2017, 16(8):696-703]

Cited: 2 times

View full text PDF listing >>



Advertisement

Disclaimer
1.1913 s